2014 Meeting Archives

Presentation Slides - February 27, 2014

Stop TB Meeting

Global epidemiology of MDR-TB
Dr. Matteo Zignol, World Health Organization, Geneva, Switzerland

Global laboratory initiative
Dr. Thomas Shinnick, Centers for Disease Control and Prevention, Atlanta, GA, USA

The global drug facility - Not available for download
Dr. Joel Keravec, World Health Organization, Geneva, Switzerland

What will it take?
Dr. Randall Reves, University of Colarado, Denver, CO, USA

Measuring the impact of community engagement on TB clinical trials
Mr. Mike Frick, Treatment Action Group, New York, NY, USA

Active TB case finding post-earthquake in a slum community in Port-au-Prince, Haiti
Mr. Jack Masur, Les Centres GHESKIO, Port-au-Prince, Haiti

Nursing-Sponsored Session

Managing complex cases
Mr. Dennis Francis, McGill University Health Centre, Montreal, QC, Canada

Managing cases through building relationships
Dr. Lisa Gurland, Lemuel Shattuck Hospital, Massachusetts Department of Public Health, Boston, MA, USA

Managing cases across boarders: US, Mexico and Central America
Dr. Carlos Vera-Garcia, Cure TB, Binational TB Program, San Diego, CA, USA

Story telling and First Nations narratives: Facilitating teaching and learning opportunities about TB in BC
Ms. Shawna Buchholz, British Columbia Centre for Disease Control, Vancouver, BC, Canada

Promoting efficacy of TB prevention and treatment in Native American communities
Ms. Denise Genaro Wolf, Public Health Seattle King County, Seattle, WA, USA

Educational resources and apporaches for managing complex TB cases
Ms. Nisha Ahamed, NJMS Global TB Institute, Newark, NJ, USA

Beyond TB Lecture:Community-based care of chronic infectious disease
Dr. Paul Farmer, Harvard Medical School / Partners in Health, Boston, MA, USA

The George Comstock Lecture: Contemporary TB control: The perfect mix of science, technology, marketing, and management capacity
(for presentation slides, please email ferguson-king@bc.lung.ca)
Dr. Catharina van Wezeenbeek, KNCV, The Hague, Netherlands

Presentation Slides - February 28, 2014

Mutli-Drug Resistant TB

Epidemiology of MDR-TB in North America / Caribbean Regions
Dr. Patrick Moonan, Centres for Disease Control and Prevention, Atlanta, GA, USA

TB drug pipeline and new treatment combinations for MDR-TB
Dr. Robert Horburgh Jr., Boston University School of Public Health, Boston, MA, USA

Management of LTBI caused by MDR-XDR isolates: The cons of susceptibility driven treatment
Dr. Sundari Mase, Centers for Disease Control and Prevention, Atlanta, GA, USA &
Dr. David Ashkin, Florida Department of Public Health, Lantana, FL, USA

Approach to fast track laboratory diagnosis for persons at risk of drug resistant TB:
   Molecular detection of drug resistance (MDDR) service
   Dr. Beverly Metchock, Centers for Disease Control and Prevention, Atlanta, GA, USA
   Advanced diagnostic laboratories
   Dr. Max Salfinger, National Jewish Medical and Research Center, Denver, CO, USA

Drug resistant profiles among patients enrolled in a cohort study of TB in Lima, Peru
Mr. Roger Ivan Calderon Espinoza, Socios en Salud Sucursal, Lima, Peru

Against all odds: Early success treating MDR-TB in the US Pacific
Dr. Richard Brostrom, Centers for Disease Control and Prevention, Honolulu, HI, USA

The Difficulty to Treat Patient

Co-mordities in TB diagnosis - Risk factors for activation
(for presentation slides, please email ferguson-king@bc.lung.ca)
Dr. Marie Turner, Lemuel Shattuck Hospital, Jamaica Plain, MA, USA

TB and the complications of substance abusing clients
Dr. Katina Forrest-Perkins, Prevent Child Abuse Minnesota, Saint Paul, MN, USA

Solving the silent crisis: Advocacy strategies to resolve and prevent domestic drug shortages
Mr. Kanyon Faroow, Treatment Action Group, New York, NY, USA

The hard to treat paediatric/adolescent patient - Not available for download
Dr. Ian Kitai and Mr. Ray Lam, Hospital for Sick Children / University of Toronto, Toronto, ON, Canada

TB exposure, infection, and disease among children with medical co-mordidities
Dr. Andrea Cruz, Baylor College of Medicine, Houston, TX, USA

Diabetes knowledge and self-management among TB patients in Hawaii, 2013
Dr. Bonnie Young, State of Hawaii Department of Health, TB Control Branch, Honolulu, HI, USA

Presentation Slides - March 1, 2014

From the Laboratory to your Clinical Practice

Targeting the organism: Present and future
Dr. Anna Upton, TB Alliance, New York, NY, USA

The host: Immunology and implications for vaccines
Dr. Tom Evans, AERAS, Rockerwille, MD, USA

Genotyping for the diagnosis of drug resistant TB
Dr, Megan Murray, Harvard School of Public Health, Boston, MA, USA

Rapid point-of-care breath test for TB
Dr. Michael Phillips, Menssana Research inc, Fort Lee, NJ, USA

Novel katG mutations identified in Myobacterium TB provide a mroe comprehensive diagnostics for Isoniazid Resistance and better clinical management of drug resistant TB
Dr. Fararmarz Valafar, San Diego State University, San Diego, CA, USA

IGRA testing using a portable incubator
Dr. Maureen Mayhew, BC Centre for Disease Control, Vancouver, BC, Canada

Latency

Evolving science of latency: Potential implications on the diagnosis and treatment of LTBI - Not available for download
Dr. JoAnne Flynn, University of Pittsburgh School of Medicince, Pittsburgh, PA, USA

Programmatic experience with IGRA testing
Dr. Julia Higashi, Curry International TB Center, San Francisco, CA, USA

Programmatic experience with the 12 dose Rifapentine/Isoniazid regimen in the US
Dr. Christine Ho, Centers for Disease Control and Prevention, Atlanta, GA, USA

Impact of screening and treatment of LTBI on TB control and incidence
   Screening and treatment as population-based control strategies
   Dr. Tim Sterling, Vanderbilt University, Nashville, TN, USA
   The limits of screening and treatment for latent TB as a TB control strategy
   Dr. Kevin Schwartzman, McGill University, Montreal, QC, Canada

Outcomes of latent TB and screening and therapy in transplant candidates and recipients over a 10 year period
Dr. Aman Sidhu, University of Alberta, Edmonton, AB, Canada

Factors associated with non-completion of latent TB infection treatment: Experiences from the Prevent TB Study
Dr. Ruth Moro, Centers for Disease Control and Prevention, Atlanata, GA, USA

Page Last Updated: 07/01/2016